<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031706</url>
  </required_header>
  <id_info>
    <org_study_id>09-1258</org_study_id>
    <secondary_id>1P50HL084934</secondary_id>
    <nct_id>NCT01031706</nct_id>
  </id_info>
  <brief_title>Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis</brief_title>
  <official_title>Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous work demonstrated that inhaled hypertonic saline (HS) reduces exacerbation frequency
      and improves lung function in adults with cystic fibrosis (CF). It is unclear, however,
      whether HS will benefit young patients suffering from CF. The investigators propose to
      further support the concept that HS can benefit children with mild CF lung disease by
      performing a relatively short, placebo controlled study of HS in 5-12 year olds, using lung
      function and mucociliary clearance as key outcome measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our current understanding of the pathogenesis of CF lung disease stems from data that
      demonstrate the presence of airway surface liquid (ASL) dehydration in CF. ASL dehydration in
      CF is caused by defective chloride secretion through the cystic fibrosis transmembrane
      regulator (CFTR) and increased sodium reabsorption through the epithelial sodium channel
      (ENaC). ASL dehydration, in turn, interferes with the mucociliary clearance apparatus,
      causing a breach in a critical line of lung host defense. A number of novel therapeutics are
      now being developed to address this basic defect of disease, including the use of inhaled
      hypertonic saline.

      Previous work demonstrated that inhaled hypertonic saline (HS) reduces exacerbation frequency
      and improves lung function in patients with clinically apparent lung disease. A number of
      issues revolving around the use of HS in CF remain unresolved. First, the typical patients
      enrolled in previous studies were adults (mean age = 26 yrs) with established lung disease
      (mean FEV1=78%). Despite our hypothesis that HS should positively affect MCC in
      preserved/normal airways, a common view of HS is that it benefits CF patients by inducing
      cough and transiently promoting the clearance of thick CF secretions. It has been questioned,
      therefore, whether HS will benefit patients who are younger and have mild (or undetectable)
      lung disease and potentially normal (though unmeasured) rates of MCC. Second, it is unclear
      whether the substantial beneficial effects of HS in CF were achieved because of a long (&gt;4
      hours) duration of action or in spite of an extremely short (~45 minutes) duration of action
      (the traditional view based upon experiments in normal epithelia). This issue is important,
      as it relates to the development and dosing of hydrator therapies that may have different
      pharmacodynamic profiles. Certainly, if twice daily dosing of a short acting compound is
      sufficient to provide significant clinical benefit, it would reduce the challenge of drug
      discovery for CF and ease the treatment burden imposed upon patients. The study of HS in CF
      provides us an opportunity to address this issue.

      The hypothesis being tested is that HS will rehydrate CF airway secretions, producing a
      sustained acceleration in MCC in young children with CF, regardless of whether a measurable
      mucus clearance defect exists at this relatively early stage of disease. We predict a
      substantial acceleration of MCC will reduce the exacerbation rate in young children with CF.
      In addition, with the growing number of treatment modalities that are prescribed to patients
      with CF, adherence to complex and time consuming medical regimens becomes increasingly
      problematic and important. We therefore, wish to test an improved drug delivery platform for
      HS- the eFlow (Pari Pharma) vibrating mesh nebulizer, which has the potential to reduce
      treatment times, improve compliance, and increase treatment efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mucociliary Clearance Rate</measure>
    <time_frame>Baseline versus after completion of 4 week treatment period</time_frame>
    <description>Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.
Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Spirometry) Change</measure>
    <time_frame>Baseline and after 4 weeks of treatment</time_frame>
    <description>Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6% NaCl, 4 ml TID via eFlow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.12% x 4ml via eFlow nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <description>inhaled HS (6% NaCl, 4mL) three times a day for 28 days</description>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <other_name>HS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 ml 0.12% NaCl inhaled three times a day x 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>.12% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Females or Males. If the subject is female and of childbearing potential
             (first menses has occurred), she must have a documented negative pregnancy test at
             screening and prior to each mucociliary clearance study. Those of childbearing
             potential must be abstinent or using an acceptable method of birth control (i.e. an
             Intrauterine Contraceptive Device with a failure rate of &lt;1%, hormonal contraceptives
             or a barrier method).

          -  Age: 5-12 years, inclusive

          -  Diagnosis: Cystic fibrosis documented by a compatible clinical presentation and sweat
             chloride &gt; 60 mEq/l or 2 disease causing CFTR mutations.

          -  Severity of the Disease: Suitable patients will have mild lung disease, as defined by:

               -  Pulmonary Function: Each patient must have an FEV1 of greater than or equal to
                  60% of predicted at the screening visit.

               -  Hemoglobin saturation: Patients must have an oxygen saturation of &gt;92% on room
                  air as determined by pulse oximetry at the screening visit.

          -  Informed consent - The patient and a parent or legally authorized guardian must agree
             to the subject's participation in the study by signing and dating the informed
             consent/assent forms after the nature of the study has been fully explained and all
             questions have been satisfactorily answered.

        Exclusion Criteria:

          -  Unstable or asthmatic lung disease: As defined by a change in medical regimen during
             the preceding 2 weeks; an FEV1 15% below recent (within 6 months) clinical
             measurements. Patients with a history of co-existent asthma, as manifested by wheezing
             and significant bronchoreactivity (&gt;15% increase in FEV1 with bronchodilator), will
             also be excluded.

          -  Other medication usage: Patients unable or unwilling to be withdrawn from hypertonic
             saline therapy for two weeks prior to Visit 1 (baseline MCC visit). Patients using
             Pulmozyme will be permitted to participate in this trial. Patients on chronic, cycling
             antibiotics will be required to have completed at least 2 full cycles of the
             prescribed antibiotic prior to enrollment and should not cycle on or off this therapy
             during the treatment period of the study.

          -  Spirometry Performance: Those subjects who are unable to perform acceptable,
             reproducible spirometry will be excluded from this study.

          -  Drug allergy: A history of allergy or intolerance to any of the study medications,
             including albuterol or hypertonic saline.

          -  Have received an investigational drug or therapy during the preceding 30 days.

          -  Have had radiation exposure within the past year that would cause them to exceed
             Federal Regulations by participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott H Donaldson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229-40.</citation>
    <PMID>16421364</PMID>
  </reference>
  <reference>
    <citation>Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006 Jan 19;354(3):241-50.</citation>
    <PMID>16421365</PMID>
  </reference>
  <reference>
    <citation>Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1796-801.</citation>
    <PMID>8665037</PMID>
  </reference>
  <reference>
    <citation>Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998 Dec 23;95(7):1005-15.</citation>
    <PMID>9875854</PMID>
  </reference>
  <reference>
    <citation>Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc Am Thorac Soc. 2004;1(1):42-6. Review.</citation>
    <PMID>16113411</PMID>
  </reference>
  <reference>
    <citation>Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med. 2006 Nov;12(6):445-52. Review.</citation>
    <PMID>17053496</PMID>
  </reference>
  <reference>
    <citation>Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003 Dec;28(8):535-45.</citation>
    <PMID>14602844</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <results_first_submitted>March 5, 2014</results_first_submitted>
  <results_first_submitted_qc>May 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2014</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Scott Donaldson, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hypertonic Saline</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Mucociliary Clearance</keyword>
  <keyword>Lung Clearance Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypertonic Saline</title>
          <description>6% NaCl, 4 ml TID via eFlow
Hypertonic Saline: inhaled HS (6% NaCl, 4mL) three times a day for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 4 ml 0.12% NaCl inhaled three times a day x 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of subjects passing screening</population>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic Saline</title>
          <description>6% NaCl, 4 ml TID via eFlow
Hypertonic Saline: inhaled HS (6% NaCl, 4mL) three times a day for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 4 ml 0.12% NaCl inhaled three times a day x 28 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="3.3"/>
                    <measurement group_id="B2" value="9.8" spread="3.6"/>
                    <measurement group_id="B3" value="11.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mucociliary Clearance Rate</title>
        <description>Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.
Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC</description>
        <time_frame>Baseline versus after completion of 4 week treatment period</time_frame>
        <population>All subjects with available data analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>6% NaCl, 4 ml TID via eFlow
Hypertonic Saline: inhaled HS (6% NaCl, 4mL) three times a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 4 ml 0.12% NaCl inhaled three times a day x 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mucociliary Clearance Rate</title>
          <description>Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.
Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC</description>
          <population>All subjects with available data analyzed</population>
          <units>percent clearance</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread=".98"/>
                    <measurement group_id="O2" value="-2.35" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Spirometry) Change</title>
        <description>Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated</description>
        <time_frame>Baseline and after 4 weeks of treatment</time_frame>
        <population>All available data included. Carry-forward of last FEV1 value (after 2 weeks of treatment) performed when data at 4 week time point not available</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>6% NaCl, 4 ml TID via eFlow
Hypertonic Saline: inhaled HS (6% NaCl, 4mL) three times a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 4 ml 0.12% NaCl inhaled three times a day x 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Spirometry) Change</title>
          <description>Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated</description>
          <population>All available data included. Carry-forward of last FEV1 value (after 2 weeks of treatment) performed when data at 4 week time point not available</population>
          <units>Percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="2.01"/>
                    <measurement group_id="O2" value="1.09" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>All events between screening and end of treatment recorded. At start of each visit, subject is asked whether they have experienced any new symptoms or problems since the prior visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hypertonic Saline</title>
          <description>6% NaCl, 4 ml TID via eFlow
Hypertonic Saline: inhaled HS (6% NaCl, 4mL) three times a day for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 4 ml 0.12% NaCl inhaled three times a day x 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>worsened steatorhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough during study drug inhalation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased sputum production</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cystic Fibrosis exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>New Pulmonary Pathogen</sub_title>
                <description>Re-aquisition of pseudmonas after prolonged negative culture; new Mycobacterium abscessus on culture</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pharynx irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>nasal/sinus congestions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott H. Donaldson</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-9198</phone>
      <email>scott_donaldson@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

